November 29, 2010 08:08 ET

Antibody Technology Sales Exceeded US $45.4 Billion in 2009

ROCKVILLE, MD--(Marketwire - November 29, 2010) - has announced the addition of La Merie S.L.'s new report "Antibody Technology Companies 2010" to their collection of Biotechnology market reports. For more information, visit

As of October 2010, 34 original therapeutic monoclonal antibodies and Fc-fusion proteins are marketed with 2009 sales exceeding US $45.4 billion. Thus, antibodies as a therapeutic modality and technology have matured and availability of new technologies as well as patent expirations offer a multitude of new options when designing an antibody-based product. While the established providers of transgenic mice have been acquired by Big Pharma/Biotech, a plethora of new antibody technologies appeared.

Although this landscape of technologies for antibody lead generation and optimization, creation of combinatorial biologics and for expression/manufacturing offers an unprecedented range of possibilities, the selection of the most robust and adequate technologies fitting to the product target profile has become more difficult than ever.

The report describes and analyzes the market size of therapeutic monoclonal antibodies and Fc-fusion proteins in 2009. Characteristics of approved antibody-based products regarding identification, construction and manufacturing are evaluated as a basis for relevant antibody technologies in 2010.

Systematic profiles of 96 companies engaged in antibody technologies serve as the basis to present in a structured manner four clusters of platform technologies (generation, optimization, novel constructs, expression/manufacturing).

The report serves as a systematic guide through the landscape of companies with antibody technologies for those in search of service providers or partners for collaboration or licensing.

Scope of the report:

  • Antibody market 2009
  • Technology analysis of 37 approved therapeutic antibody-based products
  • Profiles of 96 antibody technology companies
  • Antibody technology assessment
  • Antibody pipelines of technology companies
  • Overview of landscape of antibody technologies
  • Guide to identify suitable technologies and providers

For more information, visit

Contact Information